INTRODUCTION OBJECTIVEs METHODs REsULTs ...

7 downloads 0 Views 301KB Size Report
INTRODUCTION. • Insulin glargine is a once-daily long-acting basal insulin analog that provides effective glycemic control when administered with either oral ...
op yr ig ht pr ot ec te d. F

10

op yr ig ht pr ot ec te

10 00

Po st er s. C

3

26 (83.9)

0.6956

22 (71.0)

0.4004

18 (6.4)

10 (7.1)

0.7893

2 (6.5)

0.8991

60 (42.6)

0.5134

13 (41.9)

Statins

174 (61.9)

101 (71.6)

0.0483

18 (58.1)

ACE inhibitors

117 (41.6)

72 (51.1)

0.0662

8 (25.8)

0.3381

8.4 (1.5)

8.9 (1.6)

0.0031

8.8 (2.0)

0.9418

93.4 (34.3)

87.8 (32.6)

0.1654

80.0 (32.7)

0.0739

0.1069

C op

–14.8 (90.9)

−1.2 (2.0)

0.0018

−4.7 (25.9)

0.2349

7.2 (22.6)

0.3655

0.4581

2.2 (10.5)

0.1740

4.7 (10.7)

0.2276

0.1529

– 60.0 (173.4)

0.0250

–117.0 (182.2)

*Paired t tests for comparisons between baseline and follow-up, Lipid data was not available for all patients

yr op

Clinical Outcomes

00

0

Po

10

st

er

s.

C

• A1C was significantly reduced in each of the cohorts during the 1-year follow-up period (Table 2). • Lipid profiles were also improved during the follow-up period, with a significant reduction in LDL‑cholesterol in the GLA+ cohort, and triglycerides in the EXE+ (Table 2).

s.

st

Hypoglycemic Events/Patient

1.2

0.8

Follow-Up 6-12 Months 1.42

1.03 P = 0.54 0.65

P = 0.29

0.6

• Irrespective of how the dual treatment was initiated, combination treatment was associated with improvements in A1C without significantly increasing the percentage of patients with hypoglycemia, and was also associated with an improvement in lipid profiles.

P = 0.29

1.04

1.0

• Persistence with both treatments was low in all three cohorts, and may have been driven by the low persistence rate associated with exenatide.

0.36

0.4

0

0.09

EXE+ (n = 141)

0.23

0.12

GLA+ (n = 281)

• More randomized clinical studies are needed to confirm the clinical benefits of combination therapy with insulin glargine and exenatide in patients with T2DM.

GLA+EXE (n = 31)

B

REFERENCES 12

P = 0.3

Baseline 6 Months

9.68

10

ig



s.

er

st

0.0901

1.4

0.2

0.0018

P = 0.13

te

Suggest Documents